XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™
● Contract manufacturing of GMP drug substance and commercial-scale tablets to support the XRX-OXY-102 clinical study and future US FDA marketing approval ● CALGARY, Alberta, Sept. 10, 2026 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive […]
Financial Post
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from Financial Post.
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
Financial Post (financialpost.com), a Tier B publisher, filed this report on . CurrentWire published this page 18 minutes later, on .
Signal breakdown
CurrentWire ranked this story 59.2 of 100 in the snapshot this page was rendered from.
- Freshness
- 31.7 of 35
- Source authority
- 7 of 20
- Coverage breadth
- 4 of 20
- Geographic relevance
- 10 of 10
- Story prominence
- 6.5 of 10
- Velocity
- 0 of 5
Strongest signal: geographic relevance, 10 of 10. How each signal is calculated.
Filed under Business · US & Canada · Press release. Topics extracted from this report, with other live CurrentWire stories mentioning each: FDA (3), Calgary (4), Alberta (5), Commercial Manufacturing (none).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.